Eisai Co., Ltd. and Santen Pharmaceutical Co., Ltd. announced today that they have entered into an option agreement which grants Santen rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.
OSAKA, Japan, June 25, 2012 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. announced that Bausch + Lomb (Rochester, New York) received approval of enVista™, the first glistening-free, single-piece hydrophobic acrylic Intraocular Lens ("IOL")
OSAKA, Japan, May 8, 2012 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head office: Osaka, hereafter referred to as "Santen") announced today that Santen and Bayer Yakuhin, Ltd. (Head office: Osaka, hereafter referred to as "Bayer Yakuhin")
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Santen (SNPHF):